{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:51:35Z","timestamp":1789429895239,"version":"build-2803163510"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018695","name":"HORIZON EUROPE Research Infrastructures","doi-asserted-by":"crossref","award":["101046133"],"award-info":[{"award-number":["101046133"]}],"id":[{"id":"10.13039\/100018695","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"crossref","award":["P3-0083"],"award-info":[{"award-number":["P3-0083"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biotechnol"],"DOI":"10.1186\/s12896-025-01095-w","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T05:44:48Z","timestamp":1767159888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Purification and immunogenicity of Nipah virus-like particles from insect cells"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1365-5631","authenticated-orcid":false,"given":"Urban","family":"Bezeljak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9891-7500","authenticated-orcid":false,"given":"Alexander","family":"Jerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6591-5003","authenticated-orcid":false,"given":"Tina","family":"Kobal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8931-1756","authenticated-orcid":false,"given":"Martina","family":"Lokar Kosma\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7661-2850","authenticated-orcid":false,"given":"Elfi","family":"Birsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1003-9131","authenticated-orcid":false,"given":"Marko","family":"Kolenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9078-4923","authenticated-orcid":false,"given":"D\u00e1niel","family":"D\u00e9ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1975-4198","authenticated-orcid":false,"given":"Bernadett","family":"P\u00e1lyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Kis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matja\u017e","family":"Peterka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"1095_CR1","doi-asserted-by":"publisher","first-page":"100434","DOI":"10.1016\/j.ijregi.2024.100434","volume":"13","author":"S Khan","year":"2024","unstructured":"Khan S, Akbar SMF, Mahtab MA, Uddin MN, Rashid MM, Yahiro T, et al. Twenty-five years of Nipah outbreaks in Southeast asia: A persistent threat to global health. IJID Reg. 2024;13:100434. https:\/\/doi.org\/10.1016\/j.ijregi.2024.100434.","journal-title":"IJID Reg"},{"key":"1095_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1146\/annurev-virology-021920-113833","volume":"7","author":"M Amaya","year":"2020","unstructured":"Amaya M, Broder CC. Vaccines to emerging viruses: Nipah and Hendra. Annual Rev Virol. 2020;7:447\u201373. https:\/\/doi.org\/10.1146\/annurev-virology-021920-113833.","journal-title":"Annual Rev Virol"},{"key":"1095_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrmicro1323","volume":"4","author":"BT Eaton","year":"2006","unstructured":"Eaton BT, Broder CC, Middleton D, Wang L-F. Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol Nat Publishing Group. 2006;4:23\u201335. https:\/\/doi.org\/10.1038\/nrmicro1323.","journal-title":"Nat Rev Microbiol Nat Publishing Group"},{"key":"1095_CR4","doi-asserted-by":"publisher","first-page":"e707","DOI":"10.1016\/S1473-3099(24)00262-7","volume":"24","author":"KA Moore","year":"2024","unstructured":"Moore KA, Mehr AJ, Ostrowsky JT, Ulrich AK, Moua NM, Fay PC, et al. Measures to prevent and treat Nipah virus disease: research priorities for 2024\u201329. Lancet Infect Dis Elsevier. 2024;24:e707\u201317. https:\/\/doi.org\/10.1016\/S1473-3099(24)00262-7.","journal-title":"Lancet Infect Dis Elsevier"},{"key":"1095_CR5","doi-asserted-by":"publisher","first-page":"S493","DOI":"10.1093\/infdis\/jiz553","volume":"221","author":"MK Lo","year":"2020","unstructured":"Lo MK, Spengler JR, Welch SR, Harmon JR, Coleman-McCray JD, Scholte FEM, et al. Evaluation of a Single-Dose Nucleoside-Modified messenger RNA vaccine encoding Hendra Virus-Soluble glycoprotein against lethal Nipah virus challenge in Syrian hamsters. J Infect Dis. 2020;221:S493\u20138. https:\/\/doi.org\/10.1093\/infdis\/jiz553.","journal-title":"J Infect Dis"},{"key":"1095_CR6","doi-asserted-by":"publisher","first-page":"772864","DOI":"10.3389\/fimmu.2021.772864","volume":"12","author":"RJ Loomis","year":"2021","unstructured":"Loomis RJ, DiPiazza AT, Falcone S, Ruckwardt TJ, Morabito KM, Abiona OM, et al. Chimeric fusion (F) and attachment (G) glycoprotein antigen delivery by mRNA as a candidate Nipah vaccine. Front Immunol. 2021;12:772864. https:\/\/doi.org\/10.3389\/fimmu.2021.772864.","journal-title":"Front Immunol"},{"key":"1095_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1384417","author":"M Pedrera","year":"2024","unstructured":"Pedrera M, McLean RK, Medfai L, Thakur N, Todd S, Marsh G, et al. Evaluation of the immunogenicity of an mRNA vectored Nipah virus vaccine candidate in pigs. Front Immunol [Internet] Front. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1384417. [cited 2025 May 26];15.","journal-title":"Front Immunol [Internet] Front"},{"key":"1095_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-023-00762-3","volume":"8","author":"M Lu","year":"2023","unstructured":"Lu M, Yao Y, Zhang X, Liu H, Gao G, Peng Y, et al. Both chimpanzee adenovirus-vectored and DNA vaccines induced long-term immunity against Nipah virus infection. Npj vaccines. Nat Publishing Group. 2023;8:1\u201312. https:\/\/doi.org\/10.1038\/s41541-023-00762-3.","journal-title":"Nat Publishing Group"},{"key":"1095_CR9","doi-asserted-by":"publisher","first-page":"e58414","DOI":"10.1371\/journal.pone.0058414","volume":"8","author":"M Yoneda","year":"2013","unstructured":"Yoneda M, Georges-Courbot M-C, Ikeda F, Ishii M, Nagata N, Jacquot F, et al. Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge. PLOS ONE Public Libr Sci. 2013;8:e58414. https:\/\/doi.org\/10.1371\/journal.pone.0058414.","journal-title":"PLOS ONE Public Libr Sci"},{"key":"1095_CR10","doi-asserted-by":"publisher","first-page":"104405","DOI":"10.1016\/j.ebiom.2022.104405","volume":"87","author":"E de Wit","year":"2022","unstructured":"de Wit E, Feldmann F, Cronin J, Goldin K, Mercado-Hernandez R, Williamson BN, et al. Distinct VSV-based Nipah virus vaccines expressing either glycoprotein G or fusion protein F provide homologous and heterologous protection in a nonhuman primate model. eBioMedicine. 2022;87:104405. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104405.","journal-title":"eBioMedicine"},{"key":"1095_CR11","doi-asserted-by":"publisher","unstructured":"Foster SL, Woolsey C, Borisevich V, Agans KN, Prasad AN, Deer DJ, et al. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences; 2022;119:e2200065119. https:\/\/doi.org\/10.1073\/pnas.2200065119.","DOI":"10.1073\/pnas.2200065119"},{"key":"1095_CR12","doi-asserted-by":"publisher","unstructured":"Ithinji DG, Buchholz DW, Ezzatpour S, Monreal IA, Cong Y, Sahler J, et al. Multivalent viral particles elicit safe and efficient Immunoprotection against Nipah Hendra and Ebola viruses. NPJ vaccines [Internet]. Nature Publishing Group; 2022. [cited 2023 Feb 1];7. https:\/\/doi.org\/10.1038\/s41541-022-00588-5.","DOI":"10.1038\/s41541-022-00588-5"},{"key":"1095_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-022-00592-9","volume":"7","author":"N van Doremalen","year":"2022","unstructured":"van Doremalen N, Avanzato VA, Goldin K, Feldmann F, Schulz JE, Haddock E, et al. ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys. Npj vaccines. Nat Publishing Group. 2022;7:1\u20138. https:\/\/doi.org\/10.1038\/s41541-022-00592-9.","journal-title":"Nat Publishing Group"},{"key":"1095_CR14","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1128\/JVI.01619-06","volume":"80","author":"BA Mungall","year":"2006","unstructured":"Mungall BA, Middleton D, Crameri G, Bingham J, Halpin K, Russell G, et al. Feline model of acute Nipah virus infection and protection with a soluble Glycoprotein-Based subunit vaccine. J Virol Am Soc Microbiol. 2006;80:12293\u2013302. https:\/\/doi.org\/10.1128\/JVI.01619-06.","journal-title":"J Virol Am Soc Microbiol"},{"key":"1095_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/1743-422X-10-237","volume":"10","author":"JA Pallister","year":"2013","unstructured":"Pallister JA, Klein R, Arkinstall R, Haining J, Long F, White JR, et al. Vaccination of ferrets with a Recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months. Virol J. 2013;10:237. https:\/\/doi.org\/10.1186\/1743-422X-10-237.","journal-title":"Virol J"},{"key":"1095_CR16","doi-asserted-by":"publisher","unstructured":"Loomis RJ, Stewart-Jones GBE, Tsybovsky Y, Caringal RT, Morabito KM, McLellan JS, et al. Structure-based design of nipah virus vaccines: a generalizable approach to paramyxovirus immunogen development. Frontiers in Immunology [Internet]. 2020 [cited 2022 Nov 11];11. https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2020.00842. Accessed 11 Nov 2022.","DOI":"10.3389\/fimmu.2020.00842"},{"key":"1095_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41541-021-00284-w","volume":"6","author":"TW Geisbert","year":"2021","unstructured":"Geisbert TW, Bobb K, Borisevich V, Geisbert JB, Agans KN, Cross RW, et al. A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus. NPJ Vaccines. 2021;6:23. https:\/\/doi.org\/10.1038\/s41541-021-00284-w.","journal-title":"NPJ Vaccines"},{"key":"1095_CR18","doi-asserted-by":"publisher","first-page":"1031523","DOI":"10.3389\/fmicb.2022.1031523","volume":"13","author":"Z Gao","year":"2022","unstructured":"Gao Z, Li T, Han J, Feng S, Li L, Jiang Y, et al. Assessment of the immunogenicity and protection of a Nipah virus soluble G vaccine candidate in mice and pigs. Front Microbiol. 2022;13:1031523. https:\/\/doi.org\/10.3389\/fmicb.2022.1031523.","journal-title":"Front Microbiol"},{"key":"1095_CR19","doi-asserted-by":"publisher","first-page":"e18437","DOI":"10.1371\/journal.pone.0018437","volume":"6","author":"P Walpita","year":"2011","unstructured":"Walpita P, Barr J, Sherman M, Basler CF, Wang L. Vaccine potential of Nipah Virus-Like particles. PLOS ONE Public Libr Sci. 2011;6:e18437. https:\/\/doi.org\/10.1371\/journal.pone.0018437.","journal-title":"PLOS ONE Public Libr Sci"},{"key":"1095_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-017-0023-7","volume":"2","author":"P Walpita","year":"2017","unstructured":"Walpita P, Cong Y, Jahrling PB, Rojas O, Postnikova E, Yu S, et al. A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model. Npj Vaccines Nat Publishing Group. 2017;2:1\u20139. https:\/\/doi.org\/10.1038\/s41541-017-0023-7.","journal-title":"Npj Vaccines Nat Publishing Group"},{"key":"1095_CR21","doi-asserted-by":"publisher","first-page":"eadh4057","DOI":"10.1126\/sciadv.adh4057","volume":"9","author":"SR Welch","year":"2023","unstructured":"Welch SR, Spengler JR, Genzer SC, Coleman-McCray JD, Harmon JR, Sorvillo TE, et al. Single-dose mucosal replicon-particle vaccine protects against lethal Nipah virus infection up to 3 days after vaccination. Sci Adv. 2023;9:eadh4057. https:\/\/doi.org\/10.1126\/sciadv.adh4057.","journal-title":"Sci Adv"},{"key":"1095_CR22","doi-asserted-by":"publisher","unstructured":"Kim S, Kang H, Hyolim S, Laura S, Sahastrabuddhe S, Islam A, et al. Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response. Expert Rev Vaccines. 2025;24:183\u2013193. https:\/\/doi.org\/10.1080\/14760584.2025.2476523.","DOI":"10.1080\/14760584.2025.2476523"},{"key":"1095_CR23","doi-asserted-by":"publisher","first-page":"9953","DOI":"10.1073\/pnas.0804797105","volume":"105","author":"K Xu","year":"2008","unstructured":"Xu K, Rajashankar KR, Chan Y-P, Himanen JP, Broder CC, Nikolov DB. Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3. Proc Natl Acad Sci U S A. 2008;105:9953\u20138. https:\/\/doi.org\/10.1073\/pnas.0804797105.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1095_CR24","doi-asserted-by":"publisher","first-page":"eabe1235","DOI":"10.1126\/sciadv.abe1235","volume":"7","author":"JJ Wong","year":"2021","unstructured":"Wong JJ, Chen Z, Chung JK, Groves JT, Jardetzky TS. EphrinB2 clustering by Nipah virus G is required to activate and trap F intermediates at supported lipid bilayer\u2013cell interfaces. Sci Adv Am Association Advancement Sci. 2021;7:eabe1235. https:\/\/doi.org\/10.1126\/sciadv.abe1235.","journal-title":"Sci Adv Am Association Advancement Sci"},{"key":"1095_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.02.030","author":"BB Larsen","year":"2025","unstructured":"Larsen BB, McMahon T, Brown JT, Wang Z, Radford CE, Crowe JE, et al. Functional and antigenic landscape of the Nipah virus receptor-binding protein. Cell [Internet]. 2025. https:\/\/doi.org\/10.1016\/j.cell.2025.02.030. [cited 2025 Mar 26].","journal-title":"Cell [Internet]"},{"key":"1095_CR26","doi-asserted-by":"publisher","unstructured":"Avanzato VA, Oguntuyo KY, Escalera-Zamudio M, Gutierrez B, Golden M, Kosakovsky Pond SL, et al. A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex. Proc Natl Acad Sci. 2019;116:25057\u201367. https:\/\/doi.org\/10.1073\/pnas.1912503116.","DOI":"10.1073\/pnas.1912503116"},{"key":"1095_CR27","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41594-021-00584-8","volume":"28","author":"HV Dang","year":"2021","unstructured":"Dang HV, Cross RW, Borisevich V, Bornholdt ZA, West BR, Chan Y-P, et al. Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins. Nat Struct Mol Biol Nat Publishing Group. 2021;28:426\u201334. https:\/\/doi.org\/10.1038\/s41594-021-00584-8.","journal-title":"Nat Struct Mol Biol Nat Publishing Group"},{"key":"1095_CR28","doi-asserted-by":"publisher","unstructured":"de Wit E, Feldmann F, Cronin J, Goldin K, Mercado-Hernandez R, Williamson BN, et al. Distinct VSV-based Nipah virus vaccines expressing either glycoprotein G or fusion protein F provide homologous and heterologous protection in a nonhuman primate model. eBioMedicine [Internet]. Elsevier; 2023 [cited 2023 Aug 11];87. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104405","DOI":"10.1016\/j.ebiom.2022.104405"},{"key":"1095_CR29","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1002\/1873-3468.12272","volume":"590","author":"RE Watkinson","year":"2016","unstructured":"Watkinson RE, Lee B. Nipah virus matrix protein: expert hacker of cellular machines. FEBS Lett. 2016;590:2494\u2013511. https:\/\/doi.org\/10.1002\/1873-3468.12272.","journal-title":"FEBS Lett"},{"key":"1095_CR30","doi-asserted-by":"publisher","first-page":"e1009740","DOI":"10.1371\/journal.ppat.1009740","volume":"17","author":"D-S Ker","year":"2021","unstructured":"Ker D-S, Jenkins HT, Greive SJ, Antson AA. CryoEM structure of the Nipah virus nucleocapsid assembly. PLOS Pathogens Public Libr Sci. 2021;17:e1009740. https:\/\/doi.org\/10.1371\/journal.ppat.1009740.","journal-title":"PLOS Pathogens Public Libr Sci"},{"key":"1095_CR31","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0966-842X(03)00208-7","volume":"11","author":"R Noad","year":"2003","unstructured":"Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003;11:438\u201344. https:\/\/doi.org\/10.1016\/S0966-842X(03)00208-7.","journal-title":"Trends Microbiol"},{"key":"1095_CR32","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/14760584.2018.1516552","volume":"17","author":"B Donaldson","year":"2018","unstructured":"Donaldson B, Lateef Z, Walker GF, Young SL, Ward VK. Virus-like particle vaccines: immunology and formulation for clinical translation. Expert Rev Vaccines. 2018;17:833\u201349. https:\/\/doi.org\/10.1080\/14760584.2018.1516552.","journal-title":"Expert Rev Vaccines"},{"key":"1095_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","volume":"19","author":"S Nooraei","year":"2021","unstructured":"Nooraei S, Bahrulolum H, Hoseini ZS, Katalani C, Hajizade A, Easton AJ, et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnol BioMed Cent. 2021;19:59. https:\/\/doi.org\/10.1186\/s12951-021-00806-7.","journal-title":"J Nanobiotechnol BioMed Cent"},{"key":"1095_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/msystems.00194-19","author":"GP Johnston","year":"2019","unstructured":"Johnston GP, Bradel-Tretheway B, Piehowski PD, Brewer HM, Lee BNR, Usher NT, et al. Nipah virus-like particle egress is modulated by cytoskeletal and vesicular trafficking pathways: a validated particle proteomics analysis. mSystems Am Soc Microbiol. 2019;4:e00194-19 https:\/\/doi.org\/10.1128\/msystems.00194-19."},{"key":"1095_CR35","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jprot.2017.10.012","volume":"172","author":"NM Vera-Velasco","year":"2018","unstructured":"Vera-Velasco NM, Garc\u00eda-Murria MJ, S\u00e1nchez del Pino MM, Mingarro I, Martinez-Gil L. Proteomic composition of Nipah virus-like particles. J Proteom. 2018;172:190\u2013200. https:\/\/doi.org\/10.1016\/j.jprot.2017.10.012.","journal-title":"J Proteom"},{"key":"1095_CR36","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/biot.201400392","volume":"10","author":"CL Effio","year":"2015","unstructured":"Effio CL, Hubbuch J. Next generation vaccines and vectors: designing downstream processes for Recombinant protein-based virus-like particles. Biotechnol J. 2015;10:715\u201327. https:\/\/doi.org\/10.1002\/biot.201400392.","journal-title":"Biotechnol J"},{"key":"1095_CR37","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3390\/vaccines9080823","volume":"9","author":"A Minh","year":"2021","unstructured":"Minh A, Kamen AA. Critical assessment of purification and analytical technologies for enveloped viral vector and vaccine processing and their current limitations in resolving Co-Expressed extracellular vesicles. Vaccines. 2021;9:823. https:\/\/doi.org\/10.3390\/vaccines9080823.","journal-title":"Vaccines"},{"key":"1095_CR38","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1586\/erv.12.153","volume":"12","author":"F Fernandes","year":"2013","unstructured":"Fernandes F, Teixeira AP, Carinhas N, Carrondo MJT, Alves PM. Insect cells as a production platform of complex virus-like particles. Expert Rev Vaccines. 2013;12:225\u201336. https:\/\/doi.org\/10.1586\/erv.12.153.","journal-title":"Expert Rev Vaccines"},{"key":"1095_CR39","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/biot.201400438","volume":"10","author":"RS Felberbaum","year":"2015","unstructured":"Felberbaum RS. The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors. Biotechnol J. 2015;10:702\u201314. https:\/\/doi.org\/10.1002\/biot.201400438.","journal-title":"Biotechnol J"},{"key":"1095_CR40","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/978-1-0716-3961-0_12","volume-title":"Baculovirus: methods and protocols [Internet]","author":"D Shivhare","year":"2024","unstructured":"Shivhare D, Aw TY, Nallani M. Production of Recombinant viral antigens using the Baculovirus-Insect cell expression system. In: Cox MMJ, editor. Baculovirus: methods and protocols [Internet]. New York, NY: Springer US; 2024. pp. 185\u201394. [cited 2025 Nov 3]. https:\/\/doi.org\/10.1007\/978-1-0716-3961-0_12."},{"key":"1095_CR41","doi-asserted-by":"publisher","first-page":"e51559","DOI":"10.1371\/journal.pone.0051559","volume":"7","author":"I Margine","year":"2012","unstructured":"Margine I, Martinez-Gil L, Chou Y, Krammer F. Residual baculovirus in insect Cell-Derived influenza Virus-Like particle preparations enhances immunogenicity. PLOS ONE Public Libr Sci. 2012;7:e51559. https:\/\/doi.org\/10.1371\/journal.pone.0051559.","journal-title":"PLOS ONE Public Libr Sci"},{"key":"1095_CR42","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/elps.202200270","volume":"44","author":"T Rogerson","year":"2023","unstructured":"Rogerson T, Xi G, Ampey A, Borman J, Jaroudi S, Pappas D, et al. Purification of a Recombinant oncolytic virus from clarified cell culture media by anion exchange monolith chromatography. Electrophoresis. 2023;44:1923\u201333. https:\/\/doi.org\/10.1002\/elps.202200270.","journal-title":"Electrophoresis"},{"key":"1095_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.chroma.2016.05.053","volume":"1455","author":"P Steppert","year":"2016","unstructured":"Steppert P, Burgstaller D, Klausberger M, Berger E, Aguilar PP, Schneider TA, et al. Purification of HIV-1 gag virus-like particles and separation of other extracellular particles. J Chromatogr Elsevier B V. 2016;1455:93\u2013101. https:\/\/doi.org\/10.1016\/j.chroma.2016.05.053.","journal-title":"J Chromatogr Elsevier B V"},{"key":"1095_CR44","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nbt1095","volume":"23","author":"TA Kost","year":"2005","unstructured":"Kost TA, Condreay JP, Jarvis DL. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol. 2005;23:567\u201375. https:\/\/doi.org\/10.1038\/nbt1095.","journal-title":"Nat Biotechnol"},{"key":"1095_CR45","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.gene.2015.05.065","volume":"569","author":"AA Stepanenko","year":"2015","unstructured":"Stepanenko AA, Dmitrenko VV. HEK293 in cell biology and cancer research: phenotype, karyotype, tumorigenicity, and stress-induced genome-phenotype evolution. Gene. 2015;569:182\u201390. https:\/\/doi.org\/10.1016\/j.gene.2015.05.065.","journal-title":"Gene"},{"key":"1095_CR46","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.vaccine.2012.01.016","volume":"30","author":"MMJ Cox","year":"2012","unstructured":"Cox MMJ. Recombinant protein vaccines produced in insect cells. Vaccine Elsevier Ltd. 2012;30:1759\u201366. https:\/\/doi.org\/10.1016\/j.vaccine.2012.01.016.","journal-title":"Vaccine Elsevier Ltd"},{"key":"1095_CR47","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41587-020-0507-2","volume":"38","author":"PW Barone","year":"2020","unstructured":"Barone PW, Wiebe ME, Leung JC, Hussein ITM, Keumurian FJ, Bouressa J, et al. Viral contamination in biologic manufacture and implications for emerging therapies. Nat Biotechnol Nat Publishing Group. 2020;38:563\u201372. https:\/\/doi.org\/10.1038\/s41587-020-0507-2.","journal-title":"Nat Biotechnol Nat Publishing Group"},{"key":"1095_CR48","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3201\/eid1802.111492","volume":"18","author":"MK Lo","year":"2012","unstructured":"Lo MK, Lowe L, Hummel KB, Sazzad HMS, Gurley ES, Hossain MJ, et al. Characterization of Nipah virus from outbreaks in Bangladesh, 2008\u20132010. Emerg Infect Dis. 2012;18:248\u201355. https:\/\/doi.org\/10.3201\/eid1802.111492.","journal-title":"Emerg Infect Dis"},{"key":"1095_CR49","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.288.5470.1432","volume":"288","author":"KB Chua","year":"2000","unstructured":"Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, Lam SK, et al. Nipah virus: a recently emergent deadly paramyxovirus. Science. 2000;288:1432\u20135. https:\/\/doi.org\/10.1126\/science.288.5470.1432.","journal-title":"Science"},{"key":"1095_CR50","doi-asserted-by":"publisher","unstructured":"Weissmann F, Petzold G, \u2019t VanderLinden R et al. Veld PJ, Brown NG, Lampert F,. BiGBac enables rapid gene assembly for the expression of large multisubunit protein complexes. Proc Natl Acad Sci USA. 2016;113:E2564\u20139. https:\/\/doi.org\/10.1073\/pnas.1604935113.","DOI":"10.1073\/pnas.1604935113"},{"key":"1095_CR51","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/bit.21177","volume":"96","author":"RB Hitchman","year":"2007","unstructured":"Hitchman RB, Siaterli EA, Nixon CP, King LA. Quantitative real-time PCR for rapid and accurate Titration of Recombinant baculovirus particles. Biotechnol Bioeng. 2007;96:810\u20134. https:\/\/doi.org\/10.1002\/bit.21177.","journal-title":"Biotechnol Bioeng"},{"key":"1095_CR52","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1016\/j.vaccine.2013.07.043","volume":"31","author":"GE Smith","year":"2013","unstructured":"Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, et al. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A\/Anhui\/1\/2013 (H7N9) protection and heterologous A\/chicken\/Jalisco\/CPA1\/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine. 2013;31:4305\u201313. https:\/\/doi.org\/10.1016\/j.vaccine.2013.07.043.","journal-title":"Vaccine"},{"key":"1095_CR53","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.febslet.2004.09.009","volume":"576","author":"E Mortola","year":"2004","unstructured":"Mortola E, Roy P. Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. FEBS Lett. 2004;576:174\u20138. https:\/\/doi.org\/10.1016\/j.febslet.2004.09.009.","journal-title":"FEBS Lett"},{"key":"1095_CR54","doi-asserted-by":"publisher","first-page":"127394","DOI":"10.1016\/j.vaccine.2025.127394","volume":"61","author":"U Bezeljak","year":"2025","unstructured":"Bezeljak U, Jerman A, Kobal T, Birsa E, Lokar Kosma\u010d M, \u017diberna R, et al. Development of multivalent SARS-CoV-2 virus-like particle vaccine candidates. Vaccine. 2025;61:127394. https:\/\/doi.org\/10.1016\/j.vaccine.2025.127394.","journal-title":"Vaccine"},{"key":"1095_CR55","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.chroma.2012.10.062","volume":"1270","author":"J Lee","year":"2012","unstructured":"Lee J, Gan HT, Latiff SMA, Chuah C, Lee WY, Yang Y-S, et al. Principles and applications of steric exclusion chromatography. J Chromatogr A. 2012;1270:162\u201370. https:\/\/doi.org\/10.1016\/j.chroma.2012.10.062.","journal-title":"J Chromatogr A"},{"key":"1095_CR56","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/1743-422X-8-462","volume":"8","author":"Z Valley-Omar","year":"2011","unstructured":"Valley-Omar Z, Meyers AE, Shephard EG, Williamson A-L, Rybicki EP. Abrogation of contaminating RNA activity in HIV-1 gag VLPs. Virol J. 2011;8:462. https:\/\/doi.org\/10.1186\/1743-422X-8-462.","journal-title":"Virol J"},{"key":"1095_CR57","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1002\/jssc.201901215","volume":"43","author":"K Reiter","year":"2020","unstructured":"Reiter K, Pereira Aguilar P, Grammelhofer D, Joseph J, Steppert P, Jungbauer A. Separation of influenza virus-like particles from baculovirus by polymer-grafted anion exchanger. J Sep Sci. 2020;43:2270\u20138. https:\/\/doi.org\/10.1002\/jssc.201901215.","journal-title":"J Sep Sci"},{"key":"1095_CR58","doi-asserted-by":"publisher","unstructured":"Ang BSP, Lim TCC, Wang L. Nipah virus Infection. J Clin Microbiol. American society for microbiology; 2018;56. https:\/\/doi.org\/10.1128\/jcm.01875-17.","DOI":"10.1128\/jcm.01875-17"},{"key":"1095_CR59","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1286-4579(01)01383-1","volume":"3","author":"AD Hyatt","year":"2001","unstructured":"Hyatt AD, Zaki SR, Goldsmith CS, Wise TG, Hengstberger SG. Ultrastructure of Hendra virus and Nipah virus within cultured cells and host animals. Microbes Infect. 2001;3:297\u2013306. https:\/\/doi.org\/10.1016\/S1286-4579(01)01383-1.","journal-title":"Microbes Infect"},{"key":"1095_CR60","doi-asserted-by":"publisher","first-page":"7070","DOI":"10.1016\/j.vaccine.2019.07.001","volume":"37","author":"P Pereira Aguilar","year":"2019","unstructured":"Pereira Aguilar P, Schneider TA, Wetter V, Maresch D, Ling WL, Tover A, et al. Polymer-grafted chromatography media for the purification of enveloped virus-like particles, exemplified with HIV-1 gag VLP. Vaccine Authors. 2019;37:7070\u201380. https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.001.","journal-title":"Vaccine Authors"},{"key":"1095_CR61","doi-asserted-by":"publisher","first-page":"e1000085","DOI":"10.1371\/journal.ppat.1000085","volume":"4","author":"ML Shaw","year":"2008","unstructured":"Shaw ML, Stone KL, Colangelo CM, Gulcicek EE, Palese P. Cellular proteins in influenza virus particles. PLOS Pathogens Public Libr Sci. 2008;4:e1000085. https:\/\/doi.org\/10.1371\/journal.ppat.1000085.","journal-title":"PLOS Pathogens Public Libr Sci"},{"key":"1095_CR62","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1016\/j.vaccine.2019.07.057","volume":"37","author":"A Venereo-S\u00e1nchez","year":"2019","unstructured":"Venereo-S\u00e1nchez A, Fulton K, Koczka K, Twine S, Chahal P, Ansorge S, et al. Characterization of influenza H1N1 gag virus-like particles and extracellular vesicles co-produced in HEK-293SF. Vaccine. 2019;37:7100\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.057.","journal-title":"Vaccine"},{"key":"1095_CR63","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jprot.2017.10.012","volume":"172","author":"NM Vera-Velasco","year":"2018","unstructured":"Vera-Velasco NM, Garc\u00eda-Murria MJ, S\u00e1nchez del Pino MM, Mingarro I, Martinez-Gil L. Proteomic composition of Nipah virus-like particles. J Proteom. 2018;172:190\u2013200. https:\/\/doi.org\/10.1016\/j.jprot.2017.10.012.","journal-title":"J Proteom"},{"key":"1095_CR64","doi-asserted-by":"publisher","first-page":"6857","DOI":"10.1016\/j.vaccine.2019.09.057","volume":"37","author":"S Buffin","year":"2019","unstructured":"Buffin S, Peubez I, Barri\u00e8re F, Nicola\u00ef M-C, Tapia T, Dhir V, et al. Influenza A and B virus-like particles produced in mammalian cells are highly Immunogenic and induce functional antibodies. Vaccine. 2019;37:6857\u201367. https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.057.","journal-title":"Vaccine"},{"key":"1095_CR65","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1016\/j.vaccine.2013.05.007","volume":"31","author":"S Calabro","year":"2013","unstructured":"Calabro S, Tritto E, Pezzotti A, Taccone M, Muzzi A, Bertholet S, et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine. 2013;31:3363\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2013.05.007.","journal-title":"Vaccine"},{"key":"1095_CR66","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/14760584.2019.1578216","volume":"18","author":"HG Kelly","year":"2019","unstructured":"Kelly HG, Kent SJ, Wheatley AK. Immunological basis for enhanced immunity of nanoparticle vaccines. Expert Rev Vaccines Taylor Francis. 2019;18:269\u201380. https:\/\/doi.org\/10.1080\/14760584.2019.1578216.","journal-title":"Expert Rev Vaccines Taylor Francis"},{"key":"1095_CR67","doi-asserted-by":"publisher","first-page":"e31905","DOI":"10.1016\/j.heliyon.2024.e31905","volume":"10","author":"A Rajan","year":"2024","unstructured":"Rajan A, Nair AS, Pillai VS, Kumar B, Pai AR, Benny B, et al. Highly sensitive and quantitative HiBiT-tagged Nipah virus-like particles: A platform for rapid antibody neutralization studies. Heliyon. 2024;10:e31905. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e31905.","journal-title":"Heliyon"},{"key":"1095_CR68","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1586\/erv.10.115","volume":"9","author":"A Rold\u00e3o","year":"2010","unstructured":"Rold\u00e3o A, Mellado MCM, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in vaccine development. Expert Rev Vaccines Taylor Francis. 2010;9:1149\u201376. https:\/\/doi.org\/10.1586\/erv.10.115.","journal-title":"Expert Rev Vaccines Taylor Francis"},{"key":"1095_CR69","doi-asserted-by":"publisher","unstructured":"Moleirinho MG, Fernandes RP, Carvalho SB, Bezemer S, Detmers F, Hermans P, et al. Baculovirus affinity removal in viral-based bioprocesses. Sep Purif Technol. 2020;241. https:\/\/doi.org\/10.1016\/j.seppur.2020.116693.","DOI":"10.1016\/j.seppur.2020.116693"},{"key":"1095_CR70","doi-asserted-by":"publisher","unstructured":"Jaron M, Lehky M, Zar\u00e0 M, Zaydowicz CN, Lak A, Ballmann R et al. Baculovirus-Free SARS-CoV-2 Virus-like particle production in insect cells for rapid neutralization assessment. Viruses [Internet]. 2022 [cited 2025 Dec 4];14. https:\/\/doi.org\/10.3390\/v14102087","DOI":"10.3390\/v14102087"},{"key":"1095_CR71","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/bit.28961","volume":"122","author":"J Mahadevan","year":"2025","unstructured":"Mahadevan J, Mitra K, Giri L. An overview of Virus-Free protein expression in insect cells: A mode of rapid manufacturing platform for therapeutic protein and Virus-Like-Particles. Biotechnol Bioeng. 2025;122:1947\u201365. https:\/\/doi.org\/10.1002\/bit.28961.","journal-title":"Biotechnol Bioeng"},{"key":"1095_CR72","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","volume":"10","author":"MF Bachmann","year":"2010","unstructured":"Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10:787\u201396. https:\/\/doi.org\/10.1038\/nri2868.","journal-title":"Nat Rev Immunol"},{"key":"1095_CR73","doi-asserted-by":"publisher","unstructured":"Geisler C, Jarvis D. Insect cell glycosylation patterns in the context of biopharmaceuticals. Post-translational modif protein biopharmaceuticals. 2009;165\u201391. https:\/\/doi.org\/10.1002\/9783527626601.ch7.","DOI":"10.1002\/9783527626601.ch7"},{"key":"1095_CR74","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12250-018-0030-5","volume":"33","author":"S Dai","year":"2018","unstructured":"Dai S, Zhang T, Zhang Y, Wang H, Deng F. Zika virus Baculovirus-Expressed virus-Like particles induce neutralizing antibodies in mice. Virol Sin. 2018;33:213\u201326. https:\/\/doi.org\/10.1007\/s12250-018-0030-5.","journal-title":"Virol Sin"},{"key":"1095_CR75","doi-asserted-by":"publisher","unstructured":"He W, Tan GS, Mullarkey CE, Lee AJ, Lam MMW, Krammer F, et al. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza a virus. Proc Natl Acad Sci. 2016;113:11931\u20136. https:\/\/doi.org\/10.1073\/pnas.1609316113","DOI":"10.1073\/pnas.1609316113"},{"key":"1095_CR76","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1016\/j.vaccine.2016.08.028","volume":"34","author":"BS Pickering","year":"2016","unstructured":"Pickering BS, Hardham JM, Smith G, Weingartl ET, Dominowski PJ, Foss DL, et al. Protection against henipaviruses in swine requires both, cell-mediated and humoral immune response. Vaccine. 2016;34:4777\u201386. https:\/\/doi.org\/10.1016\/j.vaccine.2016.08.028.","journal-title":"Vaccine"},{"key":"1095_CR77","doi-asserted-by":"publisher","unstructured":"Kingstad-Bakke B, Lee W, Chandrasekar SS, Gasper DJ, Salas-Quinchucua C, Cleven T, et al. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. Proc Natl Acad Sci. 2022;119:e2118312119. https:\/\/doi.org\/10.1073\/pnas.2118312119.","DOI":"10.1073\/pnas.2118312119"},{"key":"1095_CR78","doi-asserted-by":"publisher","first-page":"e03036","DOI":"10.1128\/mbio.03036-23","volume":"15","author":"KA Bowman","year":"2023","unstructured":"Bowman KA, Kaplonek P, McNamara RP. Understanding Fc function for rational vaccine design against pathogens. mBio. Am Soc Microbiol. 2023;15:e03036\u201323. https:\/\/doi.org\/10.1128\/mbio.03036-23.","journal-title":"Am Soc Microbiol"},{"key":"1095_CR79","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41577-022-00813-1","volume":"23","author":"A Zhang","year":"2023","unstructured":"Zhang A, Stacey HD, D\u2019Agostino MR, Tugg Y, Marzok A, Miller MS. Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nat Rev Immunol Nat Publishing Group. 2023;23:381\u201396. https:\/\/doi.org\/10.1038\/s41577-022-00813-1.","journal-title":"Nat Rev Immunol Nat Publishing Group"},{"key":"1095_CR80","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/glycob\/cwr160","volume":"22","author":"JJ Aumiller","year":"2012","unstructured":"Aumiller JJ, Mabashi-Asazuma H, Hillar A, Shi X, Jarvis DL. A new glycoengineered insect cell line with an inducibly mammalianized protein N-glycosylation pathway. Glycobiology. 2012;22:417\u201328. https:\/\/doi.org\/10.1093\/glycob\/cwr160.","journal-title":"Glycobiology"}],"container-title":["BMC Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12896-025-01095-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-025-01095-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-025-01095-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:35:31Z","timestamp":1770035731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12896-025-01095-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1095"],"URL":"https:\/\/doi.org\/10.1186\/s12896-025-01095-w","relation":{"references":[{"id-type":"doi","id":"10.1128\/msystems.00194-19","asserted-by":"subject"}]},"ISSN":["1472-6750"],"issn-type":[{"value":"1472-6750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed according to the guidelines of the European Communities Council Directive (86\/609 EEC) and were approved by the Hungarian National Authority under the license numbers of National Animal Ethical Committee (PE\/EA\/00370-6\/2024; PE\/EA\/00958-6\/2024).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"UB and AJ are employees of Sferogen d.o.o., which is a vaccine development company. UB and MP are co-founders of Sferogen d.o.o. Other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}